KADIAN® capsules 20, 30, 50, 60 and 100 mg contain identical polymer coated sustained release pellets of morphine sulfate for oral administration.
KADIAN® is indicated for the management of moderate to severe pain where treatment with an opioid analgesic is indicated for more than a few days (see CLINICAL PHARMACOLOGY;
KADIAN® was developed for use in patients with chronic pain who require repeated dosing with a potent opioid analgesic, and has been tested in patients with pain due to malignant conditions. KADIAN® has not been tested as an analgesic for the treatment of acute pain or in the postoperative setting and is not recommended for such use.
Media Articles Related to Kadian (Morphine)
A decade-long effort in genetic engineering is close to re-programming yeast cells to make palliative medicines in stainless steel vats
Source: Genetics News From Medical News Today [2014.08.26]
For centuries poppy plants have been grown to provide opium, the compound from which morphine and other important medicines such as oxycodone are derived.
Tackling inflammatory pain
Source: Immune System / Vaccines News From Medical News Today [2014.08.29]
Pain from inflammation sidelines thousands of Americans each year. Many face a tough choice: deal with the pain, take a potentially addictive opioid or use a nonsteroidal anti-inflammatory drug that...
'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds
Source: MedicineNet Chronic Pain Specialty [2014.08.29]
Title: 'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds
Category: Health News
Created: 8/29/2014 9:35:00 AM
Last Editorial Review: 8/29/2014 12:00:00 AM
Iroko Pharmaceuticals gains FDA approval of ZORVOLEX® for management of osteoarthritis pain
Source: Arthritis / Rheumatology News From Medical News Today [2014.08.28]
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, has announced the United States Food and Drug Administration (FDA) has...
States that legalize medical marijuana 'have fewer deaths from opioid painkillers'
Source: Alcohol / Addiction / Illegal Drugs News From Medical News Today [2014.08.26]
Annual deaths from prescription painkillers are, on average, 25% lower in states that legalize medical marijuana, according to a new study from Johns Hopkins researchers.
Published Studies Related to Kadian (Morphine)
Periarticular infiltration of 0.25% bupivacaine on top of femoral nerve block and
intrathecal morphine improves quality of pain control after total knee
arthroplasty: a randomized double-blind placebo controlled clinical trial. 
CONCLUSION: Adding periarticular infiltration to femoral block and intrathecal
Analgesic tolerance without demonstrable opioid-induced hyperalgesia: a
double-blinded, randomized, placebo-controlled trial of sustained-release
morphine for treatment of chronic nonradicular low-back pain. 
Although often successful in acute settings, long-term use of opioid pain
medications may be accompanied by waning levels of analgesic response not readily
attributable to advancing underlying disease, necessitating dose escalation to
attain pain relief... Improvements in pain and functional ability were observed.
Tolerability and efficacy of two synergistic ratios of oral morphine and
oxycodone combinations versus morphine in patients with chronic noncancer pain. 
SETTING: Clinical study centers in Australia... CONCLUSION: A 3:2 or 1:2 fixed ratio combination of morphine and oxycodone (MOX)
Long-acting morphine following hip or knee replacement: a randomized,
double-blind and placebo-controlled trial. 
routine postoperative regimen for total hip or knee replacement surgery... CONCLUSIONS: Thirty milligrams twice per day of long-acting morphine from days 1
The effect of intravenous morphine on the level of spinal anesthesia with
CONCLUSION: Although some studies had proved the efficacy of systemic use of
Clinical Trials Related to Kadian (Morphine)
Efficacy and Safety of Intranasal Morphine for Pain After Third Molar Extraction [Completed]
This study involves approximately 200 patients designed to evaluate the efficacy and safety
of intranasal (IN) morphine 7. 5 mg and 15 mg, intravenous morphine (IV) 7. 5 mg, immediate
release oral (PO) morphine 60 mg or placebo in patients with acute postsurgical pain
following third molar extraction.
A Study of Kadian NT in Subjects With Pain Due to Osteoarthritis of the Hip or Knee [Completed]
The purpose of this study is to evaluate the efficacy of Kadian NT compared with placebo for
treating moderate to severe chronic pain over a 12 week period.
Intrathecal Morphine in Knee Arthroplasty [Completed]
This study is designed to explore the efficacy lower doses of intra-spinal morphine for pain
relief and side effect profiles of same in the setting of Total Knee Replacement. We
hypothesized that a dose greater than that used in Total Hip Replacement was needed and
wished to find a dose which was effective but had a low side effect profile.
Efficacy and Safety of Intranasal Morphine for Pain After Bunion Surgery [Completed]
Study designed to evaluate the efficacy and safety of Intranasal (IN) Morphine Nasal Spray
(MNS075) 3. 75 mg, 7. 5 mg, 15 mg, and 30 mg, intravenous (IV) morphine 7. 5 mg, or IN placebo
in patients with moderate to severe post-surgical pain following orthopedic surgery. After
initial dosing, up to six (6) doses of IN MNS075 7. 5 mg or 15 mg for up to twenty-four (24)
hours will be evaluated. The rescue dose remained the same for each.
Study of Kadian NT in Subjects With Chronic Moderate to Severe Nonmalignant Pain [Active, not recruiting]
Reports of Suspected Kadian (Morphine) Side Effects
Toxicity TO Various Agents (43),
Unresponsive TO Stimuli (40),
Completed Suicide (14),
Pulmonary Oedema (11),
Accidental Death (10),
Intentional Drug Misuse (10),
Drug Abuse (8),
Cardio-Respiratory Arrest (8),
Brain Oedema (8), more >>